H.R. 1492: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
This bill proposes an amendment to the Drug Price Negotiation Program under the Social Security Act. The key change it seeks to implement is an extension of the negotiation period for drug prices between small-molecule drugs and biologic drugs.
Specific Provisions
- The current law allows for a negotiation period of 7 years for drug prices. This bill proposes to increase that period to 11 years.
- This change aims to provide a longer timeframe for negotiations specifically for biologic drugs, which are typically more complex and costly to develop than traditional small-molecule drugs.
- The effective date of this amendment is set to be treated as if it was part of an earlier public law, specifically Public Law 117–169.
Implications
The implications of this change may include:
- Increased stability for manufacturers of biologics, as they would have a longer window to negotiate prices before they are set for Medicare and Medicaid reimbursement.
- Potential impacts on the price and availability of biologics in the market, which could affect how these drugs are accessed by patients.
- A regulatory shift that could lead to more strategic pricing strategies by pharmaceutical companies, particularly those involved in the development of biologic medications.
Potential Impact on Markets
By extending the negotiation period for biologic drugs, the bill aims to create a more balanced approach to price negotiations in the pharmaceutical industry, especially concerning the relationship between market competition and drug affordability.
Relevant Companies
- AMGN (Amgen Inc.) - As a significant producer of biologic drugs, the changes in negotiation periods could directly influence Amgen's pricing strategies and market dynamics.
- BIIB (Biogen Inc.) - With its portfolio of biologics, an extended negotiation period could affect how Biogen approaches pricing and negotiations with government programs.
- REGN (Regeneron Pharmaceuticals, Inc.) - This company, also focused on biologic therapies, could see its market strategies impacted by the proposed changes in negotiation terms.
This is an AI-generated summary of the bill text. There may be mistakes.
Sponsors
67 bill sponsors
-
TrackGregory F. Murphy
Sponsor
-
TrackRick W. Allen
Co-Sponsor
-
TrackMark E. Amodei
Co-Sponsor
-
TrackTroy Balderson
Co-Sponsor
-
TrackMichael Baumgartner
Co-Sponsor
-
TrackAaron Bean
Co-Sponsor
-
TrackCliff Bentz
Co-Sponsor
-
TrackRobert Bresnahan
Co-Sponsor
-
TrackVern Buchanan
Co-Sponsor
-
TrackKat Cammack
Co-Sponsor
-
TrackMike Carey
Co-Sponsor
-
TrackEarl L. "Buddy" Carter
Co-Sponsor
-
TrackJuan Ciscomani
Co-Sponsor
-
TrackJames Comer
Co-Sponsor
-
TrackDan Crenshaw
Co-Sponsor
-
TrackDonald G. Davis
Co-Sponsor
-
TrackNeal P. Dunn
Co-Sponsor
-
TrackGabe Evans
Co-Sponsor
-
TrackJulie Fedorchak
Co-Sponsor
-
TrackMichelle Fischbach
Co-Sponsor
-
TrackScott Fitzgerald
Co-Sponsor
-
TrackBrian K. Fitzpatrick
Co-Sponsor
-
TrackMike Flood
Co-Sponsor
-
TrackVince Fong
Co-Sponsor
-
TrackRussell Fry
Co-Sponsor
-
TrackCraig Goldman
Co-Sponsor
-
TrackMike Haridopolos
Co-Sponsor
-
TrackPat Harrigan
Co-Sponsor
-
TrackAndy Harris
Co-Sponsor
-
TrackDiana Harshbarger
Co-Sponsor
-
TrackKevin Hern
Co-Sponsor
-
TrackJ. French Hill
Co-Sponsor
-
TrackAshley Hinson
Co-Sponsor
-
TrackErin Houchin
Co-Sponsor
-
TrackRichard Hudson
Co-Sponsor
-
TrackBill Huizenga
Co-Sponsor
-
TrackBrian Jack
Co-Sponsor
-
TrackThomas H. Kean, Jr.
Co-Sponsor
-
TrackMike Kelly
Co-Sponsor
-
TrackMike Kennedy
Co-Sponsor
-
TrackBrad Knott
Co-Sponsor
-
TrackDavid Kustoff
Co-Sponsor
-
TrackRobert E. Latta
Co-Sponsor
-
TrackNicole Malliotakis
Co-Sponsor
-
TrackRichard McCormick
Co-Sponsor
-
TrackAddison McDowell
Co-Sponsor
-
TrackJohn McGuire
Co-Sponsor
-
TrackMax L. Miller
Co-Sponsor
-
TrackCarol D. Miller
Co-Sponsor
-
TrackMariannette Miller-Meeks
Co-Sponsor
-
TrackTim Moore
Co-Sponsor
-
TrackNathaniel Moran
Co-Sponsor
-
TrackZachary Nunn
Co-Sponsor
-
TrackAndrew Ogles
Co-Sponsor
-
TrackScott H. Peters
Co-Sponsor
-
TrackAugust Pfluger
Co-Sponsor
-
TrackDavid Rouzer
Co-Sponsor
-
TrackMichael A. Rulli
Co-Sponsor
-
TrackJefferson Shreve
Co-Sponsor
-
TrackAdrian Smith
Co-Sponsor
-
TrackLloyd Smucker
Co-Sponsor
-
TrackBryan Steil
Co-Sponsor
-
TrackW. Gregory Steube
Co-Sponsor
-
TrackClaudia Tenney
Co-Sponsor
-
TrackBeth Van Duyne
Co-Sponsor
-
TrackRandy K. Weber, Sr.
Co-Sponsor
-
TrackRudy Yakym III
Co-Sponsor
Actions
2 actions
| Date | Action |
|---|---|
| Feb. 21, 2025 | Introduced in House |
| Feb. 21, 2025 | Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
Corporate Lobbying
0 companies lobbying
None found.
* Note that there can be significant delays in lobbying disclosures, and our data may be incomplete.
